TrialJAMA network open2023

Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.

Xavier Pivot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.